LIVIVO - Search results -

Search results

Result 1 - 10 of total 81

Search options

Book: Nutrition and the cancer patient

Del Fabbro, Egidio

2010

Author's details	ed. by Egidio Del Fabbro
Language	English
Size	XIV, 519 S. : Ill., graph. Darst., 25 cm
Publisher	Oxford Univ. Press
Publishing place	Oxford u.a.
Publishing country	Great Britain
Document type	Book
HBZ-ID	HT016364631
ISBN	978-0-19-955019-7 ; 0-19-955019-0
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2010 A 3705	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Nutrition and the cancer patient

Del Fabbro, Egidio

2010

Author's details	ed. by Egidio Del Fabbro
Language	English
Size	XIV, 519 S. : Ill., graph. Darst., 25 cm
Publisher	Oxford Univ. Press
Publishing place	Oxford u.a.
Publishing country	Great Britain
Document type	Book
HBZ-ID	HT016364631
ISBN	978-0-19-955019-7 ; 0-19-955019-0
Database	Catalogue ZB MED Nutrition, Environment, Agriculture

In stock of ZB MED Bonn / Germany

Shelf mark	Loan status	Location
104/398	available for loan (reading room)	Freihandmagazin (U1)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Improving the perception of physician compassion, communication skills, and professionalism in the outpatient clinic.

Del Fabbro, Egidio

Cancer

2021 Volume 127, Issue 21, Page(s) 3924–3925

MeSH term(s)	Ambulatory Care Facilities ; Communication ; Empathy ; Humans ; Perception ; Physician-Patient Relations ; Physicians ; Professionalism
Language	English
Publishing date	2021-07-15
Publishing country	United States
Document type	Editorial ; Research Support, N.I.H., Extramural ; Comment
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.33776
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Hepatocellular carcinoma and sarcopenia: a narrative review.

Revoredo, Stephanie / Del Fabbro, Egidio

Annals of palliative medicine

2023 Volume 12, Issue 6, Page(s) 1295–1309

Abstract: Background and objective: Hepatocellular carcinoma (HCC) affects millions of people each year and is associated with high mortality and morbidity. Sarcopenia, a condition of muscle wasting, and decreased muscle performance is common among aging adults, ... ...

Abstract	Background and objective: Hepatocellular carcinoma (HCC) affects millions of people each year and is associated with high mortality and morbidity. Sarcopenia, a condition of muscle wasting, and decreased muscle performance is common among aging adults, and is associated with poor clinical outcomes. Individuals with HCC and chronic liver disease (CLD) are at high risk of sarcopenia because of the adverse effects of chronic inflammation, endocrine dysfunction, and hyperammonemia on muscle metabolism and adequate nutrition. Our aim is to review the clinical relationship between HCC and sarcopenia, and the assessment and management of these patients. Methods: A narrative review based on a literature search using PubMed. Keywords related to HCC and sarcopenia were used to identify relevant articles, primarily those published 2018-2023. The information was synthesized to provide a narrative review focused on the most recent literature. Key content and findings: Sarcopenia frequently co-exists with HCC and increases risk for adverse clinical outcomes such as symptom burden, quality of life (QoL), survival, and side effects of antineoplastic therapy. Tools are available to screen, assess and manage patients with HCC, and although there is no specific pharmacologic agent approved for sarcopenia in the United States, multimodal therapy is feasible in daily practice. Comprehensive management by an interdisciplinary team should include nutritional counseling, an exercise regimen and control of symptoms affecting nutrition and function. Conclusions: Sarcopenia has adverse effects on prognosis and tolerability of surgical and medical therapy in HCC. Patients with CLD and/or HCC would benefit from early identification, assessment, and therapeutic intervention. Management should be comprehensive, interdisciplinary, and include both pharmacologic and non-pharmacologic treatments. Further research is needed to identify individual agents that may mitigate muscle wasting and trials are needed to evaluate the benefit of multimodal therapy in HCC.
MeSH term(s)	Adult ; Humans ; Carcinoma, Hepatocellular/complications ; Carcinoma, Hepatocellular/therapy ; Sarcopenia/diagnosis ; Quality of Life ; Liver Neoplasms/complications ; Liver Neoplasms/therapy ; Prognosis
Language	English
Publishing date	2023-10-16
Publishing country	China
Document type	Review ; Journal Article
ZDB-ID	2828544-X
ISSN	2224-5839 ; 2224-5839
ISSN (online)	2224-5839
ISSN	2224-5839
DOI	10.21037/apm-23-332
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Should Urine Drug Screen be Done Universally or Selectively in Palliative Care Patients on Opioids?

Arthur, Joseph / Childers, Julie / Del Fabbro, Egidio

Journal of pain and symptom management

2023 Volume 66, Issue 6, Page(s) e687–e692

Abstract: Urine drug screen (UDS) is a useful test conducted in patients receiving opioids for chronic pain to aid in validating patient adherence to opioid treatment and to detect any nonmedical opioid use (NMOU). One controversial topic regarding its use in ... ...

Abstract	Urine drug screen (UDS) is a useful test conducted in patients receiving opioids for chronic pain to aid in validating patient adherence to opioid treatment and to detect any nonmedical opioid use (NMOU). One controversial topic regarding its use in palliative care is whether to conduct the test universally and randomly in all patients who are receiving opioids for chronic pain irrespective of their level of risk for NMOU, or to conduct the test selectively in only those with a high risk for engaging in NMOU behaviors. In this "Controversies in Palliative Care" article, 3 expert clinicians independently answer this question. Specifically, each expert provides a synopsis of the key studies that inform their thought processes, share practical advice on their clinical approach, and highlight the opportunities for future research. They all agreed that UDS has some utility in routine palliative care practice but acknowledged the insufficient existing evidence supporting its efficacy. They also underscored the need to improve clinician proficiency in UDS interpretation to enhance its utility. Two experts endorsed random UDS in all patients receiving opioids regardless of their risk profile while the other expert recommended targeted UDS until there is more clinical evidence to support universal, random testing. Use of more methodologically robust study designs in UDS research, examination of the cost-effectiveness of UDS tests, development of innovative programs to manage NMOU behaviors, and investigation of the impact of improved clinician proficiency in UDS interpretation on clinical outcomes, were important areas of future research that the experts identified.
MeSH term(s)	Humans ; Analgesics, Opioid/therapeutic use ; Chronic Pain/drug therapy ; Palliative Care ; Opioid-Related Disorders/therapy ; Opioid-Related Disorders/drug therapy ; Substance Abuse Detection
Chemical Substances	Analgesics, Opioid
Language	English
Publishing date	2023-07-08
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639142-4
ISSN	1873-6513 ; 0885-3924
ISSN (online)	1873-6513
ISSN	0885-3924
DOI	10.1016/j.jpainsymman.2023.06.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2252: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Combination therapy in cachexia.

Del Fabbro, Egidio

Annals of palliative medicine

2018 Volume 8, Issue 1, Page(s) 59–66

Abstract: Since Cancer cachexia is defined as a "multifactorial syndrome", an effective therapeutic approach might be comprehensive multi-faceted treatment that targets different pathophysiological mechanisms simultaneously. The defining features of cancer ... ...

Abstract	Since Cancer cachexia is defined as a "multifactorial syndrome", an effective therapeutic approach might be comprehensive multi-faceted treatment that targets different pathophysiological mechanisms simultaneously. The defining features of cancer cachexia, such as weight loss, reduced food intake, and chronic inflammation, might provide both a framework for classification of cachexia and a rationale for identifying multiple therapeutic targets. Past efforts to treat cachexia with nutritional or medical interventions may have disappointed because they were directed at a single domain of the syndrome, such as anorexia or muscle wasting, usually with a single therapeutic agent. Preliminary trials combining pharmacological and non-pharmacological therapy have been shown to be feasible and also to improve selected clinical outcomes. The choice of specific pharmacological agents has varied based on mechanistic considerations or on prior promising single intervention or multimodal trials. Despite the variations in therapy composition, most multimodal regimens share a common purpose in simultaneously modulating the major mechanisms causing cachexia, identifying patients early in the illness trajectory, and including supportive care measures such as symptom management, exercise, and nutritional counseling/supplementation.
MeSH term(s)	Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Cachexia/etiology ; Cachexia/therapy ; Combined Modality Therapy/methods ; Counseling/methods ; Dietary Supplements ; Drug Therapy, Combination ; Exercise Therapy/methods ; Fatty Acids, Omega-3/therapeutic use ; Humans ; Neoplasms/complications ; Nutritional Support ; Patient Preference ; Psychosocial Support Systems
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Fatty Acids, Omega-3
Language	English
Publishing date	2018-08-27
Publishing country	China
Document type	Journal Article ; Review
ZDB-ID	2828544-X
ISSN	2224-5839 ; 2224-5820
ISSN (online)	2224-5839
ISSN	2224-5820
DOI	10.21037/apm.2018.08.05
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Managing Nutrition Impact Symptoms in Cancer Cachexia: A Case Series and Mini Review.

Khorasanchi, Adam / Nemani, Srinidhi / Pandey, Sudeep / Del Fabbro, Egidio

Frontiers in nutrition

2022 Volume 9, Page(s) 831934

Abstract: Malnutrition is common in cancer patients and can occur throughout a patient's disease course. The contributors to the clinical syndrome of cancer cachexia are often multifactorial, and produced by the cancer and associated pro-inflammatory response. ... ...

Abstract	Malnutrition is common in cancer patients and can occur throughout a patient's disease course. The contributors to the clinical syndrome of cancer cachexia are often multifactorial, and produced by the cancer and associated pro-inflammatory response. Since cancer cachexia is a multifactorial syndrome, a multimodal therapeutic approach is ideal. A key component of therapy is identifying and managing symptom barriers to adequate oral intake, known as nutritional impact symptoms (NIS). NIS are associated with reduced intake and weight loss in patients with advanced cancer, and aggregate NIS are a predictor of survival in patients with Head and Neck Cancer and in patients undergoing surgery for esophageal cancer. Currently, there are no guidelines regarding the specific management of NIS in oncology patients. Experience from specialist centers suggest relatively simple assessments and inexpensive interventions are available for the diagnosis and treatment of NIS. We present three patient cases from a cachexia clinic, where NIS management decreased symptom burden and improved clinical outcomes such as weight and physical performance.
Language	English
Publishing date	2022-03-03
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2776676-7
ISSN	2296-861X
ISSN	2296-861X
DOI	10.3389/fnut.2022.831934
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Best Practices in the Management of Nonmedical Opioid Use in Patients with Cancer-Related Pain.

Ulker, Esad / Del Fabbro, Egidio

The oncologist

2019 Volume 25, Issue 3, Page(s) 189–196

Abstract: Introduction: Nonmedical opioid use (NMOU) in patients with cancer is a term covering a spectrum of nonprescribed opioid use. The extent to which an individual uses opioids in a nonprescribed manner will influence propensity for adverse effects such as ... ...

Abstract	Introduction: Nonmedical opioid use (NMOU) in patients with cancer is a term covering a spectrum of nonprescribed opioid use. The extent to which an individual uses opioids in a nonprescribed manner will influence propensity for adverse effects such as neurotoxicity, substance use disorder, overdose, and death. Objectives: The objectives of this study were to (A) evaluate current literature regarding management of NMOU in patients with cancer-related pain; (B) provide best practice recommendations based on evidence; and (C) integrate practices derived from the management of noncancer pain, where clinically appropriate or when the oncology literature is limited. Methods: This study is a narrative review. Implications: Although harm from NMOU was thought to be rare among oncology patients, about one in five patients with cancer is at risk of adverse outcomes including prolonged opioid use, high opioid doses, and increased health care utilization. The management of NMOU can be challenging because pain is a multidimensional experience encompassing physical, psychological, and spiritual domains. An interdisciplinary team approach is most effective, and management strategies may include (A) education of patients and families; (B) harm reduction, including opioid switching, decreasing the overall daily dose, avoiding concurrent sedative use, and using adjuvant medications for their opioid-sparing potential; (C) managing psychological and spiritual distress with an interdisciplinary team and techniques such as brief motivational interviewing; and (D) risk mitigation by pill counts, frequent clinic visits, and accessing statewide prescription drug monitoring plans. Conclusion: Although many of the management strategies for NMOU in patients with cancer-related pain are modeled on those for chronic non-cancer-related pain, there is emerging evidence that education and harm-reduction initiatives specifically for cancer-related pain are effective. Implications for practice: Nonmedical opioid use (NMOU) in patients with cancer is a term covering a broad spectrum of nonprescribed opioid use. The extent to which an individual uses opioids in a nonprescribed manner will influence propensity for adverse effects such as neurotoxicity, substance use disorder, overdose, and death. This review evaluates the evidence for best practices in oncology and addresses limitations in the literature with supplemental evidence from noncancer chronic pain. Management recommendations for NMOU are provided, based on a combination of literature-based evidence and best clinical practice. Effective management of NMOU in oncology has the potential to improve quality of life, decrease health utilization, and improve survival.
MeSH term(s)	Analgesics, Opioid/adverse effects ; Cancer Pain/drug therapy ; Chronic Pain/drug therapy ; Humans ; Neoplasms/complications ; Neoplasms/drug therapy ; Opioid-Related Disorders/drug therapy ; Opioid-Related Disorders/epidemiology ; Quality of Life
Chemical Substances	Analgesics, Opioid
Language	English
Publishing date	2019-12-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1634/theoncologist.2019-0540
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pain Management in the Era of the Opioid Crisis.

Bruera, Eduardo / Del Fabbro, Egidio

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

2018 Volume 38, Page(s) 807–812

Abstract: PRACTICAL APPLICATIONS Recognize patients at higher risk for nonmedical opioid use. Learn about screening for chemical coping risk. Diagnose nonmedical opioid use. Manage nonmedical opioid use in the clinical oncology setting. Understand clinical ... ...

Abstract	PRACTICAL APPLICATIONS Recognize patients at higher risk for nonmedical opioid use. Learn about screening for chemical coping risk. Diagnose nonmedical opioid use. Manage nonmedical opioid use in the clinical oncology setting. Understand clinical criteria for referral to supportive and palliative care teams.
MeSH term(s)	Analgesics, Opioid/administration & dosage ; Analgesics, Opioid/adverse effects ; Analgesics, Opioid/therapeutic use ; Biomarkers ; Cancer Pain/diagnosis ; Cancer Pain/etiology ; Cancer Pain/metabolism ; Cancer Pain/therapy ; Humans ; Opioid-Related Disorders ; Pain Management ; Pain Measurement ; Pain Perception/drug effects ; Practice Patterns, Physicians' ; Signal Transduction/drug effects ; Treatment Outcome
Chemical Substances	Analgesics, Opioid ; Biomarkers
Language	English
Publishing date	2018-09-19
Publishing country	United States
Document type	Journal Article ; Review
ISSN	1548-8756 ; 1092-9118 ; 1548-8748
ISSN (online)	1548-8756
ISSN	1092-9118 ; 1548-8748
DOI	10.1200/EDBK_208563
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Current and future care of patients with the cancer anorexia-cachexia syndrome.

Del Fabbro, Egidio

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

2016 , Page(s) e229–37

Abstract: Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of the cancer anorexia-cachexia syndrome (CACS) and the development of promising pharmacologic and supportive ... ...

Abstract	Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of the cancer anorexia-cachexia syndrome (CACS) and the development of promising pharmacologic and supportive care interventions. However, no approved agents for cancer cachexia currently exist, emphasizing the unmet need for an effective pharmacologic therapy. This article reviews the key elements of CACS assessment in daily practice, the contribution of nutritional impact symptoms (NIS), the evidence for current pharmacologic options, and promising anticachexia agents in perclinical and clinical trials. It also proposes a model for multimodality therapy and highlights issues pertinent to CACS in patients with pancreatic, gastric, and esophageal cancer.
MeSH term(s)	Anorexia/diagnosis ; Anorexia/drug therapy ; Anorexia/etiology ; Cachexia/diagnosis ; Cachexia/drug therapy ; Cachexia/etiology ; Humans ; Neoplasms/complications ; Neoplasms/drug therapy ; Quality of Life ; Randomized Controlled Trials as Topic
Language	English
Publishing date	2016-07-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ISSN	1548-8756 ; 1092-9118 ; 1548-8748
ISSN (online)	1548-8756
ISSN	1092-9118 ; 1548-8748
DOI	10.14694/EdBook_AM.2015.35.e229
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito